Table 2. Summary ORs (95% CI) categorized by ethnicity for the XRCC1 Arg399Gln polymorphism under different genetic models and cancer type1.
| Ethnicity | Cancer type3 | No. comparisons(SZ case/control) | Dominant model | Recessive model | Additive model | |||
| OR (95% CI) | P h /I 2 | OR (95% CI) | P h /I 2 | OR (95% CI) | P h /I 2 | |||
| Asian | Bladder cancer | 4 (956/1,388) | 0.86 (0.73–1.02) | 0.401/0.0% | 0.74 (0.56–0.99) | 0.412/0.0% | 0.71 (0.53–0.96) | 0.421/0.0% |
| Breast cancer | 9 (4,804/5,522) | 1.00 (0.93–1.08) | 0.225/24.6% | 1.20 (1.04–1.39) | 0.339/11.5% | 1.18 (1.02–1.37) | 0.269/19.5% | |
| Cervical cancer | 3 (715/1,238) | 1.07 (0.88–1.29) | 0.715/0.0% | 1.23 (0.83–1.82) | 0.841/0.0% | 1.26 (0.85–1.88) | 0.822/0.0% | |
| Colorectal cancer | 7 (2,662/4,541) | 1.07 (0.89–1.30)* | 0.003/69.4% | 1.19 (0.84–1.70)* | 0.009/67.2% | 1.22 (0.82–1.82)* | 0.002/72.8% | |
| Esophageal cancer | 6 (1,721/2,726) | 1.04 (0.82–1.32)* | 0.006/69.6% | 1.33 (0.91–1.94)* | 0.023/61.7% | 1.37 (0.88–2.14)* | 0.006/69.5% | |
| Gastric cancer | 5 (1,667/2,322) | 2 | <0.001/83.9% | 1.06 (0.83–1.32) | 0.545/0.0% | 1.01 (0.69–1.48)* | 0.070/53.9% | |
| Hepatocellularcancer | 5 (1,260/1,557) | 1.39 (1.06–1.84)* | 0.040/60.0% | 1.14 (0.88–1.46) | 0.881/0.0% | 1.32 (0.99–1.76) | 0.733/0.0% | |
| Head and neckcancer | 9 (1,718/2,018) | 1.02 (0.81–.28)* | 0.009/61.0% | 1.13 (0.88–1.45) | 0.233/23.7% | 1.11 (0.75–1.64)* | 0.058/46.9% | |
| Leukemia | 3 (431/883) | 2 | 0.001/85.6% | 0.94 (0.55–1.60) | 0.161/49.2% | 1.20 (0.37–3.89)* | 0.037/76.9% | |
| Lung cancer | 17 (6,010/6,550) | 1.07 (0.97–1.19)* | 0.031/42.9% | 1.14 (0.94–1.39)* | 0.053/39.4% | 1.16 (0.93–1.46)* | 0.013/49.5% | |
| Prostate cancer | 4 (669/762) | 1.17 (0.93–1.46) | 0.110/50.3% | 1.43 (1.02–2.00) | 0.383/1.9% | 1.55 (1.02–2.33) | 0.388/0.8% | |
| Caucasian | Bladder cancer | 13 (4,834/5,198) | 1.02 (0.94–1.11) | 0.685/0.0% | 0.91 (0.81–1.04) | 0.736/0.0% | 0.94 (0.82–1.07) | 0.650/0.0% |
| Breast cancer | 27 (18,056/18,909) | 0.99 (0.94–1.05)* | 0.036/35.6% | 0.98 (0.92–1.04) | 0.315/10.1% | 0.99 (0.92–1.05) | 0.182/19.6% | |
| Colorectal cancer | 14 (2,191/4,413) | 1.02 (0.87–1.20)* | 0.067/39.1% | 1.18 (0.91–1.54)* | 0.023/48.1% | 1.15 (0.86–1.53)* | 0.018/49.6% | |
| Esophageal cancer | 4 (568/1,233) | 0.87 (0.71–1.07) | 0.786/0.0% | 1.01 (0.74–1.38) | 0.675/0.0% | 0.95 (0.68–1.32) | 0.786/0.0% | |
| Gastric cancer | 8 (1,252/3,473) | 0.97 (0.85–1.12) | 0.317/14.4% | 1.05 (0.85–1.30) | 0.408/2.8% | 1.04 (0.83–1.30) | 0.385/5.9% | |
| Glioma | 6 (2,216/3,340) | 2 | <0.001/90.0% | 2 | <0.001/81.2% | 2 | <0.001/90.0% | |
| Head and neckcancer | 20 (4,785/7,185) | 1.02 (0.94–1.10) | 0.164/23.7% | 0.93 (0.83–1.05) | 0.223/18.6% | 0.95 (0.84–1.08) | 0.237/17.4% | |
| Leukemia | 10 (1,685/1,716) | 1.14 (0.92–1.41)* | 0.023/53.3% | 1.07 (0.87–1.30) | 0.182/28.5% | 1.17 (0.83–1.67)* | 0.013/57.1% | |
| Lung cancer | 19 (7,308/9,140) | 0.98 (0.92–1.04) | 0.560/0.0% | 1.00 (0.87–1.16)* | 0.054/38.4% | 0.99 (0.89–1.10) | 0.120/29.7% | |
| Prostate cancer | 7 (2,790/2,507) | 1.05 (0.86–1.27)* | 0.042/54.1% | 1.00 (0.84–1.18) | 0.452/0.0% | 0.96 (0.80–1.15) | 0.216/29.1% | |
| Skin cancer | 8 (3,361/3,548) | 0.94 (0.85–1.04) | 0.907/0.0% | 0.93 (0.81–1.08) | 0.212/27.1% | 0.91 (0.78–1.06) | 0.442/0.0% | |
| African | Breast cancer | 4 (1,166/1,116) | 1.28 (1.07–1.54) | 0.348/9.1% | 1.59 (0.96–2.64) | 0.918/0.0% | 1.81 (1.08–3.02) | 0.988/0.0% |
| Lung cancer | 3 (524/644) | 1.04 (0.81–1.35) | 0.682/0.0% | 0.79 (0.39–1.62) | 0.603/0.0% | 0.80 (0.39–1.64) | 0.645/0.0% | |
| Indian | Breast cancer | 3 (632/715) | 1.64 (1.31–2.04) | 0.461/0.0% | 1.94 (1.09–3.47)* | 0.037/69.8% | 2.06 (1.50–2.84) | 0.230/31.9% |
| Head and neckcancer | 3 (697/773) | 2 | <0.001/89.9% | 2 | 0.012/77.3% | 2 | <0.001/86.0% | |
| Prostate cancer | 3 (516/750) | 1.26 (1.00–1.58) | 0.207/36.5% | 2 | 0.001/86.6% | 1.30 (0.73–2.31)* | 0.024/73.0% | |
| Mixed | Breast cancer | 11 (4,891/6,357) | 1.10 (0.98–1.23)* | 0.074/41.2% | 1.00 (0.78–1.29)* | <0.001/73.5% | 1.07 (0.83–1.36)* | <0.001/68.6% |
| Colorectal cancer | 4 (2,716/3,092) | 0.99 (0.89–1.10) | 0.682/0.0% | 1.17 (0.79–1.73)* | 0.017/70.7% | 1.14 (0.79–1.65)* | 0.040/63.8% | |
| Esophageal cancer | 3 (757/2,125) | 1.06 (0.89–1.26) | 0.417/0.0% | 1.17 (0.91–1.51) | 0.805/0.0% | 1.18 (0.90–1.55) | 0.662/0.0% | |
| Head and neckcancer | 3 (592/1,430) | 0.81 (0.67–0.99) | 0.334/8.8% | 2 | 0.014/76.7% | 0.80 (0.43–1.50)* | 0.024/73.1% | |
| Skin cancer | 3 (996/1,625) | 1.06 (0.89–1.25) | 0.383/0.0% | 1.08 (0.84–1.39) | 0.470/0.0% | 1.11 (0.85–1.46) | 0.485/0.0% | |
1
all summary ORs were calculated using fixed-effects models. In the case of significant heterogeneity (indicated by *), ORs were calculated using random-effects models;
2
the results were excluded due to high heterogeneity;
3
total bladder cancer comparisons add up to 17 (which should be 20) because 1 Africans study, 1 Indians study, and 1 mixed population study did not be included. The reason is same with breast cancer, colorectal cancer, hepatocellular cancer and so on; the bold values indicate that the results are statistically significant; SZ, sample size